|Mr. Ming Xia||VP of Sales & Marketing||N/A||N/A||1974|
|Dr. Weidong Yin||Chairman, Pres, CEO, MD & Sec.||N/A||N/A||1965|
|Ms. Nan Wang||CFO & VP of Bus. Devel.||N/A||N/A||1966|
|Mr. Gao Qiang||VP of R&D||N/A||N/A||1977|
|Ms. Li Jing||VP of Quality & Production||N/A||N/A||1975|
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against enterovirus71 (EV710), hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; and split viron pandemic influenza vaccine. The company also completed phase III clinical trials for EV71, varicella, and pneumococcal polysaccharide vaccines. In addition, it has completed pre-clinical studies for sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate, Quadrivalent influenza, and rubella vaccines. The company has a collaboration agreement with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.
Sinovac Biotech Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.